Gladiola Tantaru

Dr. Gladiola Tantaru


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2025 in Polymers
Verified
Journal Article
Open access
PDF file
CVCornelia Vasile
Cornelia Vasile
GTGladiola Tantaru
Gladiola Tantaru
ACAndreea Creteanu
Andreea Creteanu
This review is an exhaustive analysis of the recent progress in the research of active and biologically active additives/ingredients. Fast-developing innovations during the last 3–5 years are included in every stage of their preparation from various resources, with valorization of the by-products and waste, characterization, arising problems with their applications, and an important role in the production of the advanced, high-performance materials. The two main well-known classes as natural (bio)active additives and nanoscaled active additives are discussed as it concerns, their types, classification, characteristic mode of action, green extraction and preparation, green synthesis, supplementary processing performed to achieve the suitable stability of the systems by micro-/nanoemulsification/encapsulation, complexation, etc., importance of the composition–activity relationships, biological effects, antimicrobial, antifungal, antioxidant potential, controlled/targeting release of (bio)active agents, the mechanisms of action of antimicrobials, antifungal and antioxidants synthesized in vivo or derived from the human diet, analytical methods for BACs characterization, degradation, toxicity concerns, a.s.o. The combinations of the two kinds of active additives (including even natural additives prepared at the nanosized level) are frequently used in research and scale-up production of new materials as important innovative solutions and challenges in various application fields, especially when their synergism appears, as will be detailed in the second part of this review.

9 October 2023 in Methods and Protocols
Verified
Journal Article
Open access
PDF file
ACAndreea Creteanu
Andreea Creteanu
GLGabriela Lisa
Gabriela Lisa
CVCornelia Vasile
Cornelia Vasile
Maria-Cristina PopescuMaria-Cristina Popescu
Maria-Cristina Popescu
ASAdrian Florin Spac
Adrian Florin Spac
GTGladiola Tantaru
Gladiola Tantaru
In various drug delivery systems, solid lipid nanoparticles are dominantly lipid-based nanocarriers. Amiodarone hydrochloride is an antiarrhythmic agent used to treat severe rhythm disturbances. It has variable and hard-to-predict absorption in the gastrointestinal tract because of its low solubility and high permeability. The aims of this study were to improve its solubility by encapsulating amiodarone into solid lipid nanoparticles using two excipients—Compritol® 888 ATO (pellets) (C888) as a lipid matrix and Transcutol® (T) as a surfactant. Six types of amiodarone-loaded solid lipid nanoparticles (AMD-SLNs) were obtained using a hot homogenization technique followed by ultrasonication with varying sonication parameters. AMD-SLNs were characterized by their size distribution, polydispersity index, zeta potential, entrapment efficiency, and drug loading. Based on the initial evaluation of the entrapment efficiency, only three solid lipid nanoparticle formulations (P1, P3, and P5) were further tested. They were evaluated through scanning electron microscopy, Fourier-transform infrared spectrometry, near-infrared spectrometry, thermogravimetry, differential scanning calorimetry, and in vitro dissolution tests. The P5 formulation showed optimum pharmaco-technical properties, and it had the greatest potential to be used in oral pharmaceutical products for the controlled delivery of amiodarone.

Verified
Journal Article
Open access
PDF file
ACAndreea Creteanu
Andreea Creteanu
GLGabriela Lisa
Gabriela Lisa
CVCornelia Vasile
Cornelia Vasile
Maria-Cristina PopescuMaria-Cristina Popescu
Maria-Cristina Popescu
PDPamfil Daniela
Pamfil Daniela
GTGladiola Tantaru
Gladiola Tantaru
The modified release of active substances such as chlorzoxazone from matrix tablets, based on Kollidon®SR and chitosan, depends both on the drug solubility in the dissolution medium and on the matrix composition. The aim of this study is to obtain some new oral matrix tablet formulations, based on Kollidon®SR and chitosan, in order to optimize the low-dose oral bioavailability of chlorzoxazone, a non-steroidal anti-inflammatory drug of class II Biopharmaceutical Classification System. Nine types of chlorzoxazone matrix tablets were obtained using the direct compression method by varying the components ratio as 1:1, 1:2, and 1:3 chlorzoxazone/excipients, 20–40 w/w % Kollidon®SR, 3–7 w/w % chitosan while the auxiliary substances: Aerosil® 1 w/w %, magnesium stearate 0.5 w/w % and Avicel® up to 100 w/w % were kept in constant concentrations. Pharmaco-technical characterization of the tablets included the analysis of flowability and compressibility properties (flow time, friction coefficient, angle of repose, Hausner ratio, and Carr index), and pharmaco-chemical characteristics (such as mass and dose uniformity, thickness, diameter, mechanical strength, friability, softening degree, and in vitro release profiles). Based on the obtained results, only three matrix tablet formulations (F1b, F2b, and F3b, containing 30 w/w % KOL and 5 w/w % CHT, were selected and further tested. These formulations were studied in detail by Fourier-transform infrared spectrometry, X-ray diffraction, thermogravimetry, and differential scanning calorimetry. The three formulations were comparatively studied regarding the release kinetics of active substances using in vitro release testing. The results were analyzed by fitting into four representative mathematical models for the modified-release oral formulations. In vitro kinetic study revealed a complex mechanism of release occurring in two steps of drug release, the first step (0–2 h) and the second (2–36 h). Two factors were calculated to assess the release profile of chlorzoxazone: f1—the similarity factor, and f2—the factor difference. The results have shown that both Kollidon®SR and chitosan may be used as matrix-forming agents when combined with chlorzoxazone. The three formulations showed optima pharmaco-technical properties and in vitro kinetic behavior; therefore, they have tremendous potential to be used in oral pharmaceutical products for the controlled delivery of chlorzoxazone. In vitro dissolution tests revealed a faster drug release for the F2b sample.

8 April 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
ACAndreea Creteanu
Andreea Creteanu
GLGabriela Lisa
Gabriela Lisa
CVCornelia Vasile
Cornelia Vasile
Maria-Cristina PopescuMaria-Cristina Popescu
Maria-Cristina Popescu
PDPamfil Daniela
Pamfil Daniela
APAlina Diana Panaite
Alina Diana Panaite
The release of the active substance from the matrix modified-release tablets based on Kollidon®SR and chitosan depends on its solubility in the dissolution medium and on the composition of the matrix-forming polymers. The study is based on new oral matrix tablets based on Kollidon®SR and chitosan, formulated to optimize the low oral bioavailability of chlorzoxazone, a non-steroidal anti-inflammatory drug, a class II Biopharmaceutical Classification System. Nine types of chlorzoxazone matrix tablets were obtained using the direct compression method, and their combination at 1:1, 1:2, 1:3 chlorzoxazone/ excipients, 20%-40% (w/w) Kollidon®SR, 3-7% (w/w) chitosan and the auxiliary substances were formulated in constant concentrations. Pharmaco-technical characterization included the analysis of flowability and compressibility properties (flow time, friction coefficient, angle of repose, Hausner ratio, Carr Index), and of pharmaco-chemical characteristics (mass and dose uniformity, thickness, diameter, mechanical strength, Friability, degree of softening, in vitro release profile) of the tablets. Based on the initial evaluation of the pharmaco-technical analysis, pharmaco-chemical characteristics, and in vitro release profile, only three matrix tablet formulations (F1b, F2b, and F3b) were further tested. They were evaluated through Fourier-transform infrared spectrometry, X-ray Diffraction, thermogravimetry, differential scanning calorimetry, and in vitro dissolution tests. The three formulations were comparatively studied regarding the release kinetics of active substances using in vitro release testing. The results were analyzed by fitting into four representative mathematical models for the modified release oral formulations. In vitro kinetic study reveals a complex mechanism of release occurring in the first (0 - 2 hours) and second (2.0 hours – 36 hours) steps of drug release. Two factors have been calculated to assess the release profile of chlorzoxazone: f1 - the similarity factor and f2 - the factor difference. The results have shown that both Kollidon®SR and chitosan may be used as matrix-forming agents when combined with chlorzoxazone. In vitro dissolution tests revealed the F2b sample, data suggesting a faster drug release. The three formulations showed optimum pharmaco-technical properties and in vitro kinetic study, and they had tremendous potential to be used in oral pharmaceutical products for the controlled delivery of chlorzoxazone.

23 March 2025 in Molecules
Verified
Journal Article
Open access
PDF file
ACAndreea Creteanu
Andreea Creteanu
GLGabriela Lisa
Gabriela Lisa
CVCornelia Vasile
Cornelia Vasile
Maria-Cristina PopescuMaria-Cristina Popescu
Maria-Cristina Popescu
PDPamfil Daniela
Pamfil Daniela
CLClaudiu N. Lungu
Claudiu N. Lungu
In the present work, the application of lignin (LIG) as a bioactive additive for the preparation of drug-loaded tablets by direct compression has been studied, and its influence on the release of chlorzoxazone (CLZ) from the hydrophilic matrices has been followed. In hydrophilic matrices, the excipients Kollidon® SR (KOL) and chitosan (CHT) have been used in various amounts and tested in the preparation of 500 mg tablets. They were used as matrix-forming agents, and their influence on the flow and the compressibility properties as well as their effect on the pharmaco-chemical characteristics of the matrix tablets have been studied. Based on the initial evaluation of the pharmaco-technical analysis, pharmaco-chemical characteristics, and in vitro release profile, three matrix tablet formulations (FLa, FLb, and FLc) were selected and further tested. They were evaluated through Fourier-transform infrared spectrometry (FTIR), X-ray diffraction (XRD), thermogravimetry (TG), differential scanning calorimetry (DSC), and in vitro dissolution tests. The three formulations were comparatively studied regarding the release kinetics of active substances using in vitro release testing. The in vitro kinetic study reveals a complex release mechanism occurring in two steps of drug release. The first one is a burst effect that occurs within the first 0–2 h, involving a rapid release of the majority of the drug in a short time, followed by the second step as a prolonged release of the drug, which is relatively constant with a fixed rate over the next 2–36 h. Two factors have been calculated to assess the release profile of chlorzoxazone: f1—the similarity factor and f2—the difference factor together with the correlation coefficient R2. Comparing their values, the three optimal formulations have been selected, containing 55 mg LIG (FLa), 60 mg LIG (FLb), or 65 mg LIG (FLc), confirming that LIG next to KOL and CHT influenced the release characteristics of the matrix tablets. Due to the presence of lignin in the matrix of the three formulations, FLa, FLb, and FLc tablets with CLZ, the antioxidant activity has improved. The antioxidant activity of FLc was found to be 21.36% ± 1.06 greater than that of FLa and FLb. The tablets FLa, FLb, and FLc also presented higher antimicrobial activity against Staphylococcus aureus, Escherichia coli, Candida albicans, and colistin-resistant Klebsiella spp. The higher the concentration of LIG in the matrix (FLc), the higher the antimicrobial activity. By using LIG, the drug dose could be decreased. It can be concluded that lignin can be used as a multifunctional pharmaceutical bioactive additive/excipient for tablets. Its interesting properties have been proven, and its use as a pharmaceutical active additive should be exploited for different applications.

19 January 2026 in Molecules
Verified
Journal Article
Open access
PDF file
PRPaula Rusu
Paula Rusu
ACAndreea Creteanu
Andreea Creteanu
Alina Mirela IpateAlina Mirela Ipate
Alina Mirela Ipate
MDMaricel Danu
Maricel Danu
MZMirela-Fernanda Zaltariov
Mirela-Fernanda Zaltariov
GLGabriela Lisa
Gabriela Lisa
Sustainable strategies for revalorizing food industry by-products are increasingly relevant in the development of modern experimental dermato-cosmetic formulations. In this study, two semisolid cosmetic creams (R10 and EM-R10) were designed using recycled palm oil—physically purified after intensive frying—as the lipid phase. The recycled oil was incorporated strictly within a controlled experimental framework and does not imply cosmetic-grade regulatory compliance. The formulations incorporated distinct bioactive profiles: R10 combined apricot and pineapple extracts with lime essential oil, while EM-R10 integrated fir bud and green tea extracts alongside the same essential oil. Both preparations contained Fragard as a preservative and niacinamide and panthenol as vitaminic components. The physicochemical properties of the formulations were assessed through rheology, confocal microscopy, ATR-FTIR, SEM, DSC, and contact angle measurements. Antimicrobial activity was evaluated against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Candida albicans using disk diffusion and broth microdilution assays. The results demonstrate that, despite partial thermal degradation, recycled palm oil retains modified structural features that influence formulation-related properties relevant to topical systems. EM-R10 showed superior spreadability, adhesion, stability, and diffusion-related performance, as well as improved antimicrobial activity, within the investigated experimental conditions, highlighting recycled palm oil as a promising sustainable lipid phase for experimental dermato-cosmetic formulations, pending further purification, toxicological evaluation, and regulatory compliance assessment.